Here, we report a case of advanced lung adenocarcinoma harboring EGFR exon 21 L858R mutations who finally achieved partial response (PR) in the lung lesion following patient-derived tumor organoid (PDTO)-guided personalized therapy, even after multiple lines of systemic treatment. This evidence concerns the gene EGFR and neoplasm.